Akoya Biosciences Inc (AKYA)
8.13
-0.22
(-2.63%)
USD |
NASDAQ |
Mar 30, 16:00
8.13
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 311.72M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -25.07% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.099 |
| Price to Book Value | 5.321 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.080 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
03/08 09:50
MT Newswires
03/06 16:05
Yahoo
03/06 16:05
Globe Newswire
02/28 08:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/05/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/05/2023* | -- | Results | Q1 2023 | -- | -0.48 | -- | |
| 03/06/2023 | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/06/2023 | -- | Results | Q4 2022 | -0.50 | -0.43 | -15.45% | |
| 11/07/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/07/2022 | -- | Results | Q3 2022 | -0.47 | -0.44 | -6.74% | |
| 08/08/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.47 | -0.36 | -32.37% |
*Estimated Date/Time
Earnings
Profile
| Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America. |
| URL | https://www.akoyabio.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Mar. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | 74.86M |
| Total Expenses (TTM) | 141.07M |
| Net Income (TTM) | -70.64M |
| Total Assets (Quarterly) | 176.03M |
| Total Liabilities (Quarterly) | 117.45M |
| Shareholders Equity (Quarterly) | 58.58M |
| Cash from Operations (TTM) | -53.50M |
| Cash from Investing (TTM) | -14.08M |
| Cash from Financing (TTM) | 28.73M |
Ratings
Profile
| Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America. |
| URL | https://www.akoyabio.com |
| Investor Relations URL | N/A |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 05, 2023 (est.) |
| Last Earnings Release | Mar. 06, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| ATL1635 | 4.427M USD | 0.56% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| AKYA Tweets |